论文部分内容阅读
目的分析通脉舒络汤联合依达拉奉治疗脑梗死的临床疗效。方法选取2013年1月~2015年6月我院脑梗死患者65例分为两组,其中对照组(32例)采用仅采用依达拉奉进行治疗;治疗组(33例)采用通脉舒络汤与依达拉奉联合治疗。对比分析两组患者的血浆同型半胱氨酸(Hcy)水平、脑梗死体积、神经功能评分以及日常生活活动能力(ADL)评价等相关临床指标。结果入院治疗时,两组患者的Hcy水平以及脑梗死体积并无显著性差异(P>0.05)。经过治疗后,治疗组患者的Hcy水平显著下降,与治疗前相比,差异有统计学意义(P<0.05)。但对照组的Hcy水平与治疗前相比,差异并不显著(P>0.05)。且治疗组患者的脑梗死体积与对照组相比显著缩小(P<0.05),组间比较差异有统计学价值。在神经功能的评分比较上,治疗组显著低于对照组(P<0.05),组间差异有统计学价值。且治疗组患者的日常生活活动能力评价优良比率显著高于对照组(P<0.05),两组之间差异显著。结论在脑梗死患者的临床治疗过程中采用通脉舒络汤与依达拉奉联合治疗方法对其进行治疗临床效果显著。
Objective To analyze the clinical effect of Tongmaishuluo Decoction combined with edaravone in the treatment of cerebral infarction. Methods Sixty-five patients with cerebral infarction in our hospital from January 2013 to June 2015 were divided into two groups. The control group (32 cases) was treated with edaravone alone. The treatment group (33 cases) Complex soup and edaravone combination therapy. The levels of plasma homocysteine (Hcy), cerebral infarction volume, neurological function scores and ADL evaluation were compared between the two groups. Results At admission, Hcy levels and infarct volume did not differ significantly between the two groups (P> 0.05). After treatment, the Hcy level of patients in the treatment group decreased significantly, compared with that before treatment (P <0.05). However, the Hcy level in the control group was not significantly different from that before treatment (P> 0.05). Compared with the control group, the volume of cerebral infarction in the treatment group was significantly reduced (P <0.05), and the differences between the two groups were statistically significant. In the comparison of neurological score, the treatment group was significantly lower than the control group (P <0.05), the difference between the groups was statistically significant. In the treatment group, the excellent rate of assessment of activities of daily living was significantly higher than that of the control group (P <0.05). There was significant difference between the two groups. Conclusions The clinical effect of Tongmaishuluo Decoction combined with edaravone in the clinical treatment of patients with cerebral infarction is significant.